Published in Drug Law Weekly, December 2nd, 2008
Net loss for the three month period ended September 30, 2008 was $1,181,406, or $0.06 per share, compared with a net loss of $382,046, or $0.02 per share, for the three month period ended September 30, 2007. This increase in net loss was primarily the result of an increase in non-cash expenses associated with the outstanding convertible notes that were issued during the year ended June 30, 2008, an increase in operating expenses and a decrease in revenue.
Quarterly and Recent Highlights
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.